"#FDA said zuranolone, sold under the brand name Zurzuvae, has been approved as a once-daily pill taken for two weeks... It is estimated that one in seven women experience symptoms of #PostPartum#Depression in the US... Clinical trials showed the pill helped to significantly reduce depressive symptoms within three days... the most common side-effects from taking Zurzuvae can include drowsiness, dizziness, diarrhoea, fatigue, the common cold, and urinary tract infection." https://www.bbc.com/news/world-us-canada-66414446
A digital health company with an app for monitoring maternal health is receiving nearly $1 million to add an algorithm for detecting a dangerous pregnancy complication.
FDA approves first oral drug for postpartum depression (www.washingtonpost.com)
It's estimated 1 in 7 women suffer from the condition after giving birth.